|
Gene: TCP1 |
Gene summary for TCP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TCP1 | Gene ID | 6950 |
Gene name | t-complex 1 | |
Gene Alias | CCT-alpha | |
Cytomap | 6q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | E7EQR6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6950 | TCP1 | Pat29-A | Human | Stomach | CAG with IM | 2.02e-08 | -3.04e-01 | -0.2769 |
6950 | TCP1 | NAG_1 | Human | Stomach | CSG | 9.50e-10 | -6.18e-01 | -0.3534 |
6950 | TCP1 | NAG_2 | Human | Stomach | CSG | 4.30e-10 | -6.76e-01 | -0.3324 |
6950 | TCP1 | NAG_3 | Human | Stomach | CSG | 1.65e-03 | -5.42e-01 | -0.2816 |
6950 | TCP1 | CAG_2 | Human | Stomach | CAG | 2.02e-07 | -5.57e-01 | -0.2831 |
6950 | TCP1 | CAG_3 | Human | Stomach | CAG | 1.20e-07 | -5.35e-01 | -0.2766 |
6950 | TCP1 | WIM_1 | Human | Stomach | WIM | 4.40e-07 | -6.13e-01 | 0.0335 |
6950 | TCP1 | WIM_2 | Human | Stomach | WIM | 7.41e-04 | -5.54e-01 | 0.1159 |
6950 | TCP1 | SIM_1 | Human | Stomach | SIM | 7.35e-14 | -6.17e-01 | 0.3573 |
6950 | TCP1 | SIM_2 | Human | Stomach | SIM | 1.39e-11 | -6.20e-01 | 0.3139 |
6950 | TCP1 | SIM_3 | Human | Stomach | SIM | 1.10e-04 | -4.67e-01 | 0.0345 |
6950 | TCP1 | SIM_4 | Human | Stomach | SIM | 1.15e-03 | -3.77e-01 | 0.2664 |
6950 | TCP1 | Pt1_Superficial | Human | Stomach | GC | 4.09e-03 | -5.20e-01 | 0.1036 |
6950 | TCP1 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 1.55e-02 | -3.63e-01 | 0.0267 |
6950 | TCP1 | PTCwithHT_6 | Human | Thyroid | HT | 6.81e-08 | -4.66e-01 | 0.02 |
6950 | TCP1 | PTCwithHT_8 | Human | Thyroid | HT | 3.16e-06 | -4.87e-01 | 0.0351 |
6950 | TCP1 | PTCwithoutHT_2 | Human | Thyroid | PTC | 2.51e-03 | -4.46e-01 | 0.0419 |
6950 | TCP1 | male-WTA | Human | Thyroid | PTC | 1.53e-51 | -5.38e-02 | 0.1037 |
6950 | TCP1 | PTC01 | Human | Thyroid | PTC | 8.66e-14 | 1.29e-01 | 0.1899 |
6950 | TCP1 | PTC03 | Human | Thyroid | PTC | 2.48e-07 | -3.07e-01 | 0.1784 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
GO:00508219 | Breast | Precancer | protein stabilization | 29/1080 | 191/18723 | 1.67e-06 | 6.08e-05 | 29 |
GO:00316479 | Breast | Precancer | regulation of protein stability | 38/1080 | 298/18723 | 3.73e-06 | 1.19e-04 | 38 |
GO:00108338 | Breast | Precancer | telomere maintenance via telomere lengthening | 15/1080 | 81/18723 | 5.31e-05 | 1.11e-03 | 15 |
GO:00007238 | Breast | Precancer | telomere maintenance | 20/1080 | 131/18723 | 6.10e-05 | 1.25e-03 | 20 |
GO:19901734 | Breast | Precancer | protein localization to nucleoplasm | 6/1080 | 14/18723 | 7.30e-05 | 1.44e-03 | 6 |
GO:20005738 | Breast | Precancer | positive regulation of DNA biosynthetic process | 13/1080 | 66/18723 | 8.54e-05 | 1.63e-03 | 13 |
GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
GO:19048743 | Breast | Precancer | positive regulation of telomerase RNA localization to Cajal body | 6/1080 | 15/18723 | 1.16e-04 | 2.08e-03 | 6 |
GO:19048516 | Breast | Precancer | positive regulation of establishment of protein localization to telomere | 5/1080 | 10/18723 | 1.25e-04 | 2.21e-03 | 5 |
GO:00070047 | Breast | Precancer | telomere maintenance via telomerase | 13/1080 | 69/18723 | 1.37e-04 | 2.38e-03 | 13 |
GO:19043567 | Breast | Precancer | regulation of telomere maintenance via telomere lengthening | 12/1080 | 61/18723 | 1.61e-04 | 2.69e-03 | 12 |
GO:19043588 | Breast | Precancer | positive regulation of telomere maintenance via telomere lengthening | 9/1080 | 37/18723 | 1.96e-04 | 3.10e-03 | 9 |
GO:00702034 | Breast | Precancer | regulation of establishment of protein localization to telomere | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:19048694 | Breast | Precancer | regulation of protein localization to Cajal body | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:19048714 | Breast | Precancer | positive regulation of protein localization to Cajal body | 5/1080 | 11/18723 | 2.18e-04 | 3.35e-03 | 5 |
GO:00062786 | Breast | Precancer | RNA-dependent DNA biosynthetic process | 13/1080 | 75/18723 | 3.27e-04 | 4.64e-03 | 13 |
GO:0035036 | Breast | Precancer | sperm-egg recognition | 10/1080 | 48/18723 | 3.43e-04 | 4.81e-03 | 10 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCP1 | SNV | Missense_Mutation | novel | c.1640N>G | p.Asp547Gly | p.D547G | P17987 | protein_coding | tolerated_low_confidence(0.12) | benign(0.007) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
TCP1 | deletion | Frame_Shift_Del | c.1430delN | p.Asn477ThrfsTer7 | p.N477Tfs*7 | P17987 | protein_coding | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |||
TCP1 | SNV | Missense_Mutation | novel | c.1555N>C | p.Glu519Gln | p.E519Q | P17987 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
TCP1 | SNV | Missense_Mutation | novel | c.396N>G | p.Ile132Met | p.I132M | P17987 | protein_coding | tolerated(0.2) | possibly_damaging(0.706) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TCP1 | SNV | Missense_Mutation | c.1438N>T | p.Arg480Cys | p.R480C | P17987 | protein_coding | deleterious(0.02) | possibly_damaging(0.579) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | |
TCP1 | SNV | Missense_Mutation | c.10N>T | p.Pro4Ser | p.P4S | P17987 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
TCP1 | SNV | Missense_Mutation | novel | c.501N>A | p.Phe167Leu | p.F167L | P17987 | protein_coding | tolerated(0.26) | benign(0.044) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TCP1 | SNV | Missense_Mutation | rs760874138 | c.1297N>T | p.Arg433Trp | p.R433W | P17987 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-5255-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
TCP1 | SNV | Missense_Mutation | c.1064N>T | p.Arg355Ile | p.R355I | P17987 | protein_coding | deleterious(0.03) | possibly_damaging(0.781) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
TCP1 | SNV | Missense_Mutation | novel | c.944N>G | p.Asp315Gly | p.D315G | P17987 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |